Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
With Hartalega (HARTA) hovering around RM1.00 after its stellar Q1 FY2027 results, many investors are focusing on the volatility of Average Selling Prices (ASP) and the threat of Chinese competition. However, I believe the market is missing the bigger picture.
My conviction in this company is not based on the "war-driven ASP spike." It is based on Management’s capital allocation discipline and their structural cost advantage. Here is why I believe Hartalega remains the only relevant Malaysian glove maker for the long haul:
1. The "Efficiency Gap" vs. Chinese Competitors
We often hear that Chinese players (like Intco) will "undercut everyone." However, look at the hard numbers: Hartalega’s Plant 9 (NGC 1.5) reduces manufacturing costs by 16% and lowers headcount by 8% using AI vision systems and automated stripping.
The Chinese business model of "薄利多销" (small margins, high volume) works in a bull market, but it is unsustainable when raw material (NBR) costs spike and ASPs drop. When you sell at US$18-20 per 1,000 pieces, who survives? The manufacturer with the lowest cost per unit. Hartalega is consistently pushing that cost floor lower, while their competitors are bleeding cash to keep their massive factories running.
2. Capital Allocation: The Top Glove Contrast
If you want to see the difference between a "survivor" and a "casualty," look at the history of capital allocation. During the pandemic boom, many competitors (specifically Top Glove) misallocated billions by aggressively buying back shares at the absolute peak of the stock price (draining cash) and over-expanding.
Hartalega’s management did the opposite. They hoarded RM1.14 Billion in cash, maintained practically zero net debt, and only initiated share buybacks when the stock was trading below RM0.90 (as seen in their recent buyback records). They did not chase the meme-stock hype. They protected their balance sheet. This is the hallmark of a rational, long-term management team.
3. The US and European "Certification" Moat
Price is only one factor in the US and European medical supply chains. Quality and regulatory compliance are the true barriers to entry. It takes years of stringent audits (FDA 510k, CE Marking, ISO 13485) and proven reliability to become a trusted supplier to major US hospital networks.
When Chinese manufacturers redirect excess capacity to non-US markets to survive, they are fighting a price war in regions that will trade quality for cost. However, the $60 billion+ US/EU medical market will still pay a premium for reliability. Hartalega’s automation ensures consistency, and their long-standing track record ensures they remain relevant in these high-value markets.
4. The "Oil Tanker" Risk (The Cash Cushion)
The biggest risk to Hartalega today is the gas tariff hike and the NBR cost mismatch in Q2. However, even with a projected 65% drop in next quarter’s profits, Hartalega is not at risk of bankruptcy. They have RM1.14 Billion in cash, no net debt, and a 60% dividend policy. They can weather a 2-3 year price war while the weaker players (both local and Chinese) burn through their cash.
Conclusion:
The market is treating Hartalega like a "trading play" based on the Iran war. I treat it as a "Cigar Butt" with a generational capital allocator at the helm. I do not expect the stock to return to RM4.00. However, I am confident that over the next 3-5 years, Plant 9’s cost efficiencies and management’s disciplined capital deployment will allow Hartalega to steadily grow its EPS back to pre-war normalized levels.
When everyone is fighting over a shrinking pie, I'm betting on the one with the sharpest knife and the deepest pockets.
This is a clear positive for shareholders(short-to-medium term).
· Why it’s good: It proves that PPB’s core business is actively winning new work. A 241-day contract (with a 30-day extension option) guarantees steady revenue and utilization for that vessel well into 2027.
· What’s missing: The contract value is not disclosed (due to confidentiality). You don’t know the exact profit margin. However, because they are providing "crew and equipment" for 24-hour service, this is typically a high-margin, recurring revenue stream.
· Key date: The contract starts 9 July 2026 (just days away), so the cash flow benefit will begin almost immediately.
2. The Share Capital Reduction (High Court Order Granted)
This is a neutral-to-positive accounting exercise (long-term impact).
· What happened: The High Court approved the reduction on 30 July 2026. The company now just needs to lodge the sealed order with SSM (Companies Commission) for it to take effect.
· Is it cash or a book adjustment? it is strictly a book adjustment. There is no mention of cash payout.
· Why the company does this: Perdana likely uses this to wipe out accumulated losses on their balance sheet. By clearing past losses, their retained earnings account becomes clean.
· Why it matters to shareholders :
· No immediate cash — your wallet is unaffected.
· Future dividends: With accumulated losses wiped out, PPB will be legally able to pay dividends from future profits. This paves the way for potential cash returns to shareholders in the years ahead.
· Clean balance sheet: It makes the company look healthier to investors and banks, which helps them secure future loans for things like those new AHTS vessels they are building.
Let’s use the Munger/Buffett "Invert" principle to dissect,
On Cost in China is way lower than Malaysia." (Reality: FALSE)
This is the biggest myth being spread right now.
· The Data: In the Kenanga report, it explicitly stated: "Through automation, Malaysian glove makers have reduced production costs by ~20%, significantly narrowing the cost gap with Chinese manufacturers."
· Why it matters: China's Intco does not have a massive cost advantage anymore. Hartalega's Plant 9 automation has brought their cost per 1,000 pieces down to ~RM16.80. Chinese factories have rising labor costs and environmental compliance costs. The cost difference today is razor-thin.
On Supply way more than demand." (Reality: TRUE for Medical Gloves)
· Global capacity is ~530B pieces; demand is ~373B pieces. There is massive oversupply.
· However, this is a problem for weak players. Hartalega is not a weak player. In a price war, the strongest survivor wins. Hartalega has zero net debt and RM1.14 billion in cash. When the oversupply forces small, debt-ridden factories to close, Hartalega will pick up their market share at pennies on the dollar.
On Wasting time on this industry... spend time on other MOATs.
This is where you are partially right.
You are right that medical gloves do not have a permanent, 30-year moat. The moat is only temporary (cost automation).
However, if you look at the UOB Riverstone report, that proves that Cleanroom / Semiconductor gloves DO have a permanent moat.
· Why? Because it takes 20+ years of trust and stringent quality certifications to supply an AI/Semiconductor chip factory. Chinese competitors cannot easily break into that market.
The market is always right about the supply-demand math in the short term. But the market is frequently wrong about the long-term survivability of the best-in-class operator.
The person who bought at RM20.00 during the COVID mania was not an investor; they were a gambler. They bought a commodity stock at a 100x PE ratio during a once-in-a-century pandemic, thinking the mania would last forever.
Charlie Munger’s view on this:
"The first rule of an investment is: Don't lose money. The second rule is: Never forget rule number one."
The person who bought at RM20 has already broken both rules. The market does not care about their loss. The share price is not sitting at RM0.965 because of them; it is sitting there because of industry oversupply. The "pity" you feel is an emotional trap designed to make you fearful.
1. The Immediate Impact: The "NBR Shortage" is BACK
· In March, traffic collapsed to near-zero.
· It briefly recovered in early July (the spike we see).
· But in late July, The traffic have dropped again to almost zero.
What this triggers:
Nitrile Butadiene Rubber (NBR)—the key raw material for nitrile gloves—is heavily dependent on crude oil and petrochemical shipments passing through this strait.
If the strait closes again, NBR supply will tighten massively. We saw this in March/April, which pushed Average Selling Prices (ASPs) from US28 per 1,000 pieces.
The market will immediately anticipate that NBR prices will spike, forcing glove makers to raise ASPs again to protect margins.
2. The "Irrational" Market Reaction Must Watch For
Here is the psychological irony of the market:
· Yesterday's News: The unconfirmed rumor about Trump "ending" the deal sent a false signal that war was escalating. It caused a brief, confused rally.
· Today's Chart reported by The Financial Times: This is actual, verified data (Lloyd's List Intelligence) showing ships are not moving. This is a concrete supply shock.
Potential scenario: When the mainstream financial media picks up this FT chart (within the next 24 hours), retail and institutional traders will start buying glove stocks again.
However, do not get euphoric. The market learned a hard lesson in June: Geopolitical disruptions are temporary. As soon as the strait reopens, ASPs will crash again.
3. The Strategic Impact on August QR
This chart is a massive tailwind for the August quarterly report (April–June 2026).
· The April–June quarter captured the first Hormuz closure (March).
· Now, this July disruption means that the next quarter (July–Sept) might also see elevated ASPs.
· The takeaway: Hartalega is going to report explosive profits for August. And if the strait remains blocked through August/September, they will report another strong quarter in November.
4. The ONE Risk to Watch (The "Temporary" Trap)
The FT chart also shows a brief recovery in early July. If this current closure is just a 2-week blip (e.g., ships waiting for a new negotiation), ASPs might only stay high for a month.
· If the strait reopens fully by August, the stock price could collapse right after the August QR is released, because the market will look forward to Q3/Q4 and see ASPs falling again.
Summary: This FT chart proves the NBR supply disruption is real and ongoing, not a one-time event.
If we apply the logic of Munger and Buffett, is Hartalega a classic "post-pandemic supply-demand imbalance" cyclical play—an opportunity to be greedy when others are fearful, and potentially buy a multi-bagger for the future? Given that Hartalega's resource allocation focuses on automation to reduce human labor (which is its moat), and it doesn't recklessly deploy capital, instead keeping a war chest for emergencies and waiting to acquire good assets—is this considered responsible management?
Let us stepped out of the retail mindset of "chasing price movements" and evaluating a company through the lens of Charlie Munger's "Mental Models" and Warren Buffett's "Capital Allocation."
From the perspective of Munger and Buffett, Hartalega currently displays the classic characteristics of a "contrarian cyclical investment," and its management is indeed practicing responsible capital allocation.
Let's break this down into three dimensions:
1. The Munger Lens: The Pendulum of "Fear" and "Greed" (Human Nature & Cycles)
Munger famously said: "The market is like a giant pendulum that swings back and forth between extreme optimism and extreme pessimism, rarely stopping in the middle."
· What is the current fear? The market sees ASPs crashing from US18, and China's Intco aggressively expanding. As a result, they declare the glove industry "dead" and hammer Hartalega's stock down to RM 0.98 (a 25% discount to its RM 1.30 Net Asset Value).
· Where is the seed of greed? The global economy still needs gloves (essential demand). At the cycle's trough, the weak (high-cost, small factories) go bankrupt, while strong players like Hartalega survive and thrive using their automation advantage.
· Does Hartalega fit "Be greedy when others are fearful"? Yes, from an industry cycle standpoint. But remember, Munger and Buffett emphasize: "Don't try to catch a falling knife." They require buying a company that is extremely undervalued with an incredibly strong moat. Hartalega's moat is strong enough to keep it from dying, but how much it earns depends on the supply-demand rebalancing over the next 3 years. As long as it doesn't go bankrupt, RM 0.98 is near the bottom of the cycle.
2. The Buffett Lens: Is the Moat Real? (Resource Concentration)
Buffett says: "A true moat is when customers are willing to pay more for your product, not because you sell it cheaper."
· Hartalega's moat is NOT a "brand"—it's a "structural cost advantage." Buffett would view this cost advantage built through automation as a real moat, but its width is "cyclical."
· Why haven't they "deployed capital recklessly" into M&A? This is exactly where Hartalega's management mirrors Buffett the most!
· Many companies (like Intco) went on a massive factory-building and acquisition spree during the pandemic windfall, leading to today's massive overcapacity.
· Hartalega didn't blindly expand capacity. Instead, they focused entirely on upgrading Plant 9 with AI vision detection and high automation. This is like Buffett—he never buys random businesses; he uses retained earnings to improve the ROE (Return on Equity) of his existing core operations.
· Conclusion: Hartalega is concentrating its capital on "cost reduction and efficiency," rather than adding to excess capacity. This is highly disciplined and responsible capital allocation.
3. The "Cash Hoard" Moat: Waiting for the Right Assets
This is a principle Munger deeply admires: "The Art of Waiting."
· Munger says: "Great people don't seize every daily opportunity. They wait decades for one fantastic opportunity, and then bet heavily."
· Hartalega is sitting on a cash pile of RM 1.14 billion. In the brutal "bloodbath" of the glove industry (current global capacity 530 billion pieces vs. demand 370 billion), many small factories will go bankrupt from losses.
· Hartalega's future overtaking opportunity: When those high-cost Chinese or Malaysian small factories are forced to sell their plants or equipment, Hartalega (with its RM 1.14 billion) can act like a "vulture" and acquire quality assets at fire-sale prices. This "patient, predatory" capital strategy is exactly the kind of cash reserve strategy Buffett most admires.
The Ultimate Verdict: Is Hartalega a "Multi-Bagger" Potential?
(The Math of Future Potential from Absolute Valuation)
1. Normalized Price Floor Estimate: Assume ASP stabilizes at US18). Hartalega's annualized EPS can sustain around 4.0 sen. At a mature industrial PE of 15-20x, the fair price is RM 0.60 - RM 0.80.
2. What is the current price (RM 0.98) trading on? The current price has already "discounted" the normal floor. It is trading on the "panic premium"—the market thinks it will die. But it won't; it has RM 1.1 billion in cash.
3. Where is the "multi-bagger" potential? Not from industry recovery, but from "industry consolidation + buying distressed assets." If Hartalega can use its RM 1.1 billion over the next 2-3 years to absorb market share or factories from bankrupt competitors, its EPS could jump to 8.0 - 10.0 sen in 3 years. At that point, a share price of RM 1.50 - RM 2.00 is highly probable (a 2x-bagger).
